Oxidative injury is a common consequence of BMPR2 mutations

Pulmonary Circulation

Volumn 1, Issue 1, 2011, Pages 72-83

  Lane, Kirk L ^a   Talati, Megha ^a   Austin, Eric ^a   Hemnes, Anna R ^a   Johnson, Jennifer A ^a   Fessel, Joshua P ^a   Blackwell, Tom ^a   Mernaugh, Ray L ^b   Robinson, Linda ^a   Fike, Candice ^a   Roberts, L Jackson ^a,b   West, James ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Born morphogenetic protein receptor II; Idiopathic and heritable pulmonary arterial hypertension; Signal transduction

Indexed keywords

EID: 84863249942     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.78107     Document Type: Article

References (46)

1. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGFbeta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-4.
2. Cogan JD, Vnencak-Jones CL, Phillips JA 3rd, Lane KB, Wheeler LA, Robbins IM, et al. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 2005;7:169-74.
3. ten Dij ke P, Korchynskyi O, Valdimarsdott ir G, Goumans MJ. Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol 2003;211:105-13.
4. Folett a VC, Lim MA, Soosairajah J, Kelly AP, Stanley EG, Shannon M, et al. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 2003;162:1089-98.
5. West J, Harral J, Lane K, Deng Y, Ickes B, Crona D, et al. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 2008;295:L744-55.
6. Sankelo M, Flanagan JA, Machado R, Harrison R, Rudarakanchana N, Morrell N, et al. BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension. Hum Mutat 2005;26:119-24.
7. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002;11:1517-25.
8. Yang J, Davies RJ, Southwood M, Long L, Yang X, Sobolewski A, et al. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res 2008;102:1212-21.
9. Herpin A, Cunningham C. Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes. FEBS J 2007;274:2977-85.
10. Austin ED, Phillips JA, Cogan JD, Hamid R, Yu C, Stanton KC, et al. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res 2009;10:87.
11. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-6.
12. Zhang B, Schmoyer D, Kirov S, Snoddy J. GO Tree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 2004;5:16.
13. Morrow JD, Scruggs J, Chen Y, Zackert WE, Roberts LJ 2nd. In vivo Evidence that the E2-isoprostane, 15-E2t-isoprostane (8-iso-prostaglandin E2) is formed. J Lipid Res 1998;39:1589-93.
14. Tada Y, Majka S, Carr M, Harral J, Crona D, Kuriyama T, et al. Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. Am J Physiol Lung Cell Mol Physiol 2007;292:L1556-63.
15. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc 2006;3:680-6.
16. Johnson J, Hemnes A, Lane K, Robinson L, Gladson S, West J. ACE2 Reverses Established Pulmonary Arterial Hypertension in BMPR2R899X Mice. Paper presented at: American Thoracic Society International Conference. New Orleans, Louisiana;2010.
17. Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem 1997;253:162-8.
18. Münzel T, Afanas’ev IB, Kleschyov AL, Harrison DG. Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol 2002;22: 1761-8.
19. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med 2008;5:338-49.
20. Johnson CD, Balagurunathan Y, Dougherty ER, Afshari CA, He Q, Ramos KS. Insight into redox-regulated gene networks in vascular cells. Bioinformation 2007;1:379-83.
21. Tai HH, Cho H, Tong M, Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des 2006;12:955-62.
22. The Gene Ontology in 2010: extensions and refinements. Nucleic Acids Res 2010;38:D331-5.
23. Milne GL, Yin H, Brooks JD, Sanchez S, Jackson Roberts L 2nd, Morrow JD. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007;433:113-26.
24. Fessel JP, Jackson Roberts L. Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in sett ings of elevated oxygen tension. Antioxid Redox Signal 2005;7:202-9.
25. Brooks C, Wei Q, Cho SG, Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009;119:1275-85.
26. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/ reperfusion injury. Circulation 2010;121:2012-22.
27. Davies SS, Amarnath V, Roberts LJ 2nd. Isoketals: highly reactive gammaketoaldehydes formed from the H2-isoprostane pathway. Chem Phys Lipids 2004;128:85-99.
28. Robbins IM, Morrow JD, Christman BW. Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic Biol Med 2005;38:568-74.
29. Grunig E, Weissmann S, Ehlken N, Fij alkowska A, Fischer C, Fourme T, et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009;119:1747-57.
30. Firth AL, Yuan JX. Bringing down the ROS: a new therapeutic approach for PPHN. Am J Physiol Lung Cell Mol Physiol 2008;295:L976-8.
31. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
32. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A 2007;104:1342-7.
33. Rehman J, Archer SL. A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol 2010;661:171-85.
34. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta 2010;1797:897-906.
35. Chen CA, Druhan LJ, Varadharaj S, Chen YR, Zweier JL. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. J Biol Chem 2008;283:27038-47.
36. Naka K, Muraguchi T, Hoshii T, Hirao A. Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal 2008;10:1883-94.
37. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-52.
38. Hunter KS, Albietz JA, Lee PF, Lanning CJ, Lammers SR, Hofmeister SH, et al. In vivo measurement of proximal pulmonary artery elastic modulus in the neonatal calf model of pulmonary hypertension: development and ex-vivo validation. J Appl Physiol 2010;108:968-75.
39. Yao H, Yang SR, Kode A, Rajendrasozhan S, Caito S, Adenuga D, et al. Redox regulation of lung inflammation: role of NADPH oxidase and NF-kappaB signalling. Biochem Soc Trans 2007;35:1151-5.
40. West J. Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension. Adv Exp Med Biol 2010;661:265-78.
41. Bereiter-Hahn J, Vöth M, Mai S, Jendrach M. Structural implications of mitochondrial dynamics. Biotechnol J 2008;3:765-80.
42. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008;294:H570-8.
43. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008;99: 989-94.
44. Shanmugam M, McBrayer SK, Rosen ST. Targeting the Warburg effect in hematological malignancies: from PET to therapy. Curr Opin Oncol 2009;21:531-6.
45. Rippe C, Lesniewski L, Connell M, Larocca T, Donato A, Seals D. Shortterm Calorie Restriction Reverses Vascular Endothelial Dysfunction in Old Mice by Increasing Nitric Oxide and Reducing Oxidative Stress. Aging Cell 2010;9:304-12.
46. Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials. Curr Med Chem 2010;17:672-97.